PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

Figure the transfer of the tra	•	
To: RONALD J. BARON	PCT	
HOFFMANN & BARON, LLP 6900 JERICHO TURNPIKE SYOSSET, NY 11791	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION	
	(PCT Rule 44.1)	
	Date of mailing (day/month/year) 23 SEP 2005	
Applicant's or agent's file reference 178-330 PCT	FOR FURTHER ACTION See paragraphs 1 and 4 below	
International application No. PCT/US04/36027	International filing date (day/month/year) 28 October 2004 (28.10.2004)	
Applicant STATE UNIVERSITY OF NEW YORK		
The applicant is hereby notified that the international sea have been established and are transmitted herewith.	arch report and the written opinion of the International Searching Authority	
Filing of amendments and statement under Article 19 The applicant is entitled, if he so wishes, to amend the cl	experience: aims of the international application (see Rule 46):	
When? The time limit for filing such amendments is search report.	s normally two months from the date of transmittal of the international	
Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Facsimile No.: +41 22 740 14 35		
For more detailed instructions, see the notes on the	accompanying sheet.	
2. The applicant is hereby notified that no international sear Article 17(2)(a) to that effect and the written opinion of	rch report will be established and that the declaration under the International Searching Authority are transmitted herewith.	
3. With regard to the protest against payment of (an) add	litional fee(s) under Rule 40.2, the applicant is notified that:	
the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.		
	pplicant will be notified as soon as a decision is made.	
4. Reminders		
Bureau. If the applicant wishes to avoid or postpone publicat priority claim, must reach the International Bureau as provided technical preparations for international publication.	ate, the international application will be published by the International tion, a notice of withdrawal of the international application, or of the in Rules 90bis.1 and 90bis.3, respectively, before the completion of the	
The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.		
Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.		
	ths (or later) will apply even if no demand is filed within 19 months.	
Volume II, National Chapters and the WIPO Internet site.	applicable time limits, Office by Office, see the PCT Applicant's Guide,	
Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US	Authorized officer	

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703) 305-3230
Form PCT/ISA/220 (January 2004) (See notes on accompanying sheet)

Telephone No. 571-272-0700

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 178-330 PCT		Form PCT/ISA/220 ere applicable, item 5 below.
International application No. PCT/US04/36027	International filing date (day/month/year) 28 October 2004 (28.10.2004)	(Earliest) Priority Date (day/month/year) 30 October 2003 (30.10.2003)
Applicant STATE UNIVERSITY OF NEW YORK		
This international search report has been according to Article 18. A copy is being This international search report consists. It is also accompanied 1. Basis of the Report a. With regard to the language, the language in which it was filed, un The international to this Authority b. With regard to any nucleoti 2. Certain claims were found 3. Unity of invention is lacking the text is approved as submitted.	of a total of sheets. I by a copy of each prior art document cited international search was carried out on the bashless otherwise indicated under this item. I search was carried out on the basis of a transle (Rule 23.1(b)). I de and/or amino acid sequence disclosed in the unsearchable (See Box No. II) In g (See Box No. III)	in this report. is of the international application in the ation of the international application furnished
may, within one month from	nitted by the applicant. I, according to Rule 38.2(b), by this Authority n the date of mailing of this international searc	as it appears in Box No. IV. The applicant h report, submit comments to this Authority.
as suggested by the	Authority, because the applicant failed to sugg	est a figure.
b. as selected by this	Authority, because this figure better charactering published with the abstract.	zes the invention.

Form PCT/ISA/210 (first sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/36027

A. CLASSIFICATION OF SUBJECT MATTER		
IPC(7) : A61K 31/35; C07D 305/00		
US CL: 514/449; 549/510,511 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/449; 549/510,511		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name	of data base and, where practicable, search terms used)	
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category * Citation of document, with indication, where ap		
X US 5,795,909 A (SHASHOUA et al) 18 April 1998 (thru column 8 line 7; example 2.	18.04.1998), claims, clumn 7 line 35	
,		
	·	
Further documents are listed in the continuation of Box C.	See patent family annex.	
Special categories of cited documents:	"T" later document published after the international filing date or priority	
"A" document defining the general state of the art which is not considered to be of particular relevance	date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination	
"O" document referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the art	
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family	
Date of the actual completion of the international search	Date of mailing of the international search report 2.3 SEP 2009	
17 August 2005 (17.08.2005) Name and mailing address of the ISA/US	Authorized officer	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450	Amelia A. Owens Telephone No. 571-272-0700	
Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	1 Telephone No. 3/1-2/2-0/00	

Form PCT/ISA/210 (second sheet) (January 2004)

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTH	ORITY		
To: RONALD J. BARON HOFFMANN & BARON, LLP 6900 JERICHO TURNPIKE		PCT	
SYOSSET, NY 11791			ITTEN OPINION OF THE DNAL SEARCHING AUTHORITY
(PCT Rule 43 <i>bis</i> .1)			(PCT Rule 43bis.1)
		Date of mailing (day/month/year)	23 SEP 2009
Applicant's or agent's file reference		FOR FURTHER	ACTION See paragraph 2 below
178-330 PCT	The simulation date	(day/month/soan)	Priority date (day/month/year)
International application No.	International filing date		
PCT/US04/36027 International Patent Classification (IPC)	or both national classificat		30 October 2003 (30.10.2003)
IPC(7): A61K 31/35; C07D 305/00 and	US Cl.: 514/449; 549/510,:	511	
Applicant			
STATE UNIVERSITY OF NEW YORK	<u> </u>		
This opinion contains indications re	lating to the following iten	ns:	
Box No. I Basis of the opinion			
Box No. II Priority			
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
Box No. IV Lack of unity of invention			
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
Box No. VI Certain do	cuments cited		
Box No. VII Certain defects in the international application			
Box No. VIII Certain ob	servations on the internation	onal application	
2. FURTHER ACTION			
International Preliminary Examini	ing Authority ("IPEA") e the IPEA and the chosen	except that this does IPEA has notified t	be considered to be a written opinion of the not apply where the applicant chooses an he International Bureau under Rule 66.1bis(b) lered.
IPEA a written reply together, whe	ere appropriate, with amen e expiration of 22 months f	dments, before the ex	PEA, the applicant is invited to submit to the contraction of 3 months from the date of mailing whichever expires later.
For further options, see Form PCT/	ISA/220.		
3. For further details, see notes to For	m PCT/ISA/220.		_
Name and mailing address of the ISA/ L	JS	Authorized offic	
Mail Stop PCT, Attn: ISA/US		Kull Vuchson	
Commissioner for Patents P.O. Box 1450			$O'' = A \sim \lambda \lambda $
P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. 571-272-0700			

Facsimile No. (703) 305-3230

Form PCT/ISA/237 (cover sheet) (January 2004)



WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/36027

Box No. 1 Basis of this opinion
1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
This opinion has been established on the basis of a translation from the original language into the following language which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
a. type of material
a sequence listing
table(s) related to the sequence listing
b. format of material
in written format
in computer readable form
c. time of filing/furnishing
contained in international application as filed.
filed together with the international application in computer readable form.
furnished subsequently to this Authority for the purposes of search.
In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:
·

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/36027

1. Statement Novelty (N) Claims 1-71 Claims NONE Claims NONE Inventive step (IS) Claims NONE Claims 1-71 NO Industrial applicability (IA) Claims 1-71 Claims 1-71 Claims NONE Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention as the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosshexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purieve of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the expected properties lacks inventive step given the teachings of Shashoua et al.	Box No. V Reasoned statement under Rule 4 applicability; citations and explan	3 <i>bis</i> .1(a)(i) ations supp	with regard to novelty, inventive step or orting such statement	r industrial
Inventive step (IS) Claims NONE Claims NONE Claims 1-71 NO Industrial applicability (IA) Claims 1-71 Claims NONE Claims 1-71 YES Claims NONE NO 2. Citations and explanations: Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention at the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	1. Statement			
Inventive step (IS) Claims NONE Claims NONE Claims 1-71 NO Industrial applicability (IA) Claims 1-71 Claims NONE Claims 1-71 YES Claims NONE NO 2. Citations and explanations: Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention at the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	Novelty (N)	Claims	1-71	YES
Industrial applicability (IA) Claims 1-71 YES Claims 1-71 YES Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention as the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the				
Industrial applicability (IA) Claims 1-71 YES Claims 1-71 YES Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention as the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	Inventing stan (IS)	Claima	NONE	VFS
Claims NONE 2. Citations and explanations: Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention at the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	inventive step (13)			
Claims NONE 2. Citations and explanations: Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention at the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the				
2. Citations and explanations: Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention as the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	Industrial applicability (IA)			
Claims 1-71 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention as the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the		Claims	NONE	NO
be made or used in industry. Claims 1-71 meet the criteria set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the claimed invention as the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	2. Citations and explanations:			
the specific taxane and omega 3 fatty acid conjugate. Thus, the claims are novel. Claims 1-71 lack an inventive step under PCT Article 33(3) as being obvious over Shashoua et al USP 5,795,909 which teach conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the		3(4), and thus	have industrial applicability because the subject	et matter claimed can
conjugates of cis-docosahexanonic acid (omega 3 fatty acid) and taxanes used to treat cell proliferative disorders. Omega 3 fatty acids are known to be combinable with taxanes to produce conjugates; and taxanes are known to treat cell proliferation. Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	Claims 1-71 meet the criteria set out in PCT Article 3 the specific taxane and omega 3 fatty acid conjugate.	3(2), because Thus, the clai	the prior art does not teach or fairly suggest the ms are novel.	e claimed invention as
Replacement of a compound with another compound belonging to the same class, in this instance taxane and omega 3 fatty acids, is we within the purview of the skilled artisan. Further, combining a taxane and an omega 3 fatty acid to arrive at a conjugate, which as the	Claims 1-71 lack an inventive step under PCT Article conjugates of cis-docosahexanonic acid (omega 3 fatt	e 33(3) as being ty acid) and ta	g obvious over Shashoua et al USP 5,795,909 vanes used to treat cell proliferative disorders.	which teach
	Replacement of a compound with another compound within the purview of the skilled artisan. Further, cor	belonging to t mbining a taxa	he same class, in this instance taxane and omeg ne and an omega 3 fatty acid to arrive at a conj	ga 3 fatty acids, is well
		-		
·				
Form PCT/ISA/237 (Box No. V) (January 2004)	DCT/(CA/227 (Day No. 12) (1 2004)		·	

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/36027

Box No. VIII	Certain observations on the international application
	servations on the clarity of the claims, description, and drawings or on the questions whether the claims are fully

supported by the description, are made: Claim 1, 41 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because claims 1, 41 are indefinite for the following reason(s): the claims begin with the word 'in' which render them confusing and ambiguous. It is suggested the word be